FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
4D Molecular Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$12.29+0.15 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $863.64M
- P/E (TTM)
- –
- Dividend yield
- –
4D Molecular Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Market Cap | $887.09M | $164.85M |
| Enterprise Value | $545.34M | $87.06M |
| PS Ratio | 9.64 | 3.60 |
| PB Ratio | 2.18 | 2.03 |
| P/TBV Ratio | 2.18 | 2.31 |
Enterprise value
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 5.93 | 2.43 |
Income (trailing twelve months)
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Revenue | $92.01M | $57.94M |
| Operating Income | -$197.12M | -$21.44M |
| Net Income | -$179.18M | -$22.46M |
| EBITDA | -$192.09M | -$16.91M |
| EPS (Diluted) | -$2.76 | -$0.83 |
Margins
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -214.2% | -44.5% |
| Profit Margin | -194.7% | -39.2% |
| EBITDA Margin | -208.8% | -31.3% |
Returns
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -43.3% | -53.1% |
| Return on Assets (ROA) | -37.1% | -41.0% |
| Return on Invested Capital (ROIC) | -160.9% | -32.0% |
| Return on Capital Employed (ROCE) | -44.3% | -37.8% |
Growth
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 278712.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 200.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 44.3% | 6.42% |
Balance sheet
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $361.33M | $62.42M |
| Total Debt | $19.59M | $120.13M |
| Net Cash (Debt) | $341.75M | $15.68M |
| Net Cash Per Share | $4.73 | $0.66 |
| Equity (Book Value) | $407.66M | $48.79M |
| Book Value Per Share | $5.65 | $1.36 |
| Tangible Book Value | $407.66M | $23.06M |
| Working Capital | $335.28M | $75.77M |
Financial position
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 8.03 | 3.30 |
| Quick Ratio | 7.58 | 2.39 |
| Debt / Equity | 0.05 | 0.51 |
Cash flow (trailing twelve months)
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$156.07M | -$12.35M |
Efficiency
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.19 | 0.38 |
| Revenue Per Employee | $469.43K | $398.96K |
| Profits Per Employee | -$914.16K | -$703.34K |
| Employee Count | 196 | 74 |
Dividends and yields
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -20.2% | -22.7% |
Shares
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 72,179,900 | 58,179,650 |
| Shares Change (YoY) | 15.9% | 11.1% |
| Shares Change (QoQ) | 5.63% | 0.54% |
| Float | 70,609,100 | 49,173,100 |
| Shares Held by Insiders | 2.18% | 11.6% |
| Shares Held by Institutions | 80.5% | 59.4% |
Taxes
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | 4D Molecular Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 3.51 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from 4D Molecular Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.